Skip to content Skip to footer
Subscribe Now
Viewpoints_Nikki Longwell
VIEWPOINTS

PharmaShots Interview: Janssen’s Nikki Longwell Shares Insights on the National Biologic Coordinators Day

In an interview with PharmaShots, Nikki Longwell, Sr. Director, Medical Science Liaisons, Immunology at Janssen shares her views on the launch of the National Biologic Coordinators Day supporting the needs of people living with autoimmune diseases Shots: The company has launched the first national awareness day “National Biologic Coordinators Day” on Nov 1 which is also known as a day…
January 17, 2022

Read more

PharmaShots Interview Medicago’s Brian Ward Shares Insights on the Data of Plant-Based COVID-19 Vaccine
VIEWPOINTS

PharmaShots Interview: Medicago’s Brian Ward Shares Insights on the Data of Plant-Based COVID-19 Vaccine

In an interview with PharmaShots, Brian Ward, Medical Officer at Medicago shares his views on the P-III study of plant-based COVID-19 vaccine in combination with GSK’s pandemic adjuvant for the treatment of COVID-19  Shots: The company reported efficacy and safety results from the P-III study of Medicago’s plant-based COVID-19 vaccine candidate + GSK’s pandemic adjuvant in ~24,000 adults aged ≥18yrs. across Canada, US, UK,…
January 12, 2022

Read more

PharmaShots Interview Insmed’s Martina Flammer Shares Insights on New Affordable Drugs for Rare Diseases
VIEWPOINTS

PharmaShots Interview: Insmed’s Martina Flammer Shares Insights on New Affordable Drugs for Rare Diseases

In an interview with PharmaShots, Martina Flammer, Chief Medical Officer at Insmed share her views on the R&D continuum to develop new drugs for rare diseases and also highlights its business pillars Shots: The idea of the continuum is that all department works together to develop the drugs which will be helpful not only for the company but for patients too In…
January 11, 2022

Read more

Deal Maker of the Year 2021 (Part 01)
INSIGHTS+

Deal Maker of the Year 2021 (Part 01)

Shots: AstraZeneca and Roche were the top dealmakers completed 33 deals with multiple pharma and biotech companies and universities for a total deal value of $6.2B & $25.83B The highest value deal was AstraZeneca’s partnership with Ionis for the development and commercialization of Eplontersen signed on Dec. 7, 2021. Merck and Pfizer are among the…
January 7, 2022

Read more

Insights+ Key Biosimilars Events of December 2021
INSIGHTS+

Insights+ Key Biosimilars Events of December 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of December, Samsung Bioepis presented five-year follow-up results of…
January 6, 2022

Read more

Viewpoints_Dr. Justin Odegaard_Dr. Yoshiaki Nakamura
VIEWPOINTS

PharmaShots Interview: Guardant Health’s Justin Odegaard Shares Insights on the Data of Guardant360 Liquid Biopsy Test Published in Nature Medicine

In an interview with PharmaShots, Justin Odegaard, Vice President of Clinical Development and a Laboratory Director at Guardant Health & Yoshiaki Nakamura, Staff Physician in the Department of Gastroenterology and Gastrointestinal Oncology shared their views on the benefits of using the Guardant360 liquid biopsy test in P-II (TRIUMPH) study for HER2-driven metastatic colorectal cancer Shots: The P-II (TRIUMPH) study evaluates pertuzumab +…
January 5, 2022

Read more

PharmaShots Interview Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology
VIEWPOINTS

PharmaShots Interview: Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology

In an interview with PharmaShots, Alyssa Johnsen, MD, Ph.D., Vice President, Rheumatology and Maternal-Fetal Health Disease Area Leader at Janssen Research & Development shares her views on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in ACR 2021 and published in Arthritis & Rheumatology Shots: The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739…
January 4, 2022

Read more

PharmaShots Interview Alto Neuroscience’s Dr. Amit Etkin Shares Insights on the Future of Psychiatric Medicines
VIEWPOINTS

PharmaShots Interview: Alto Neuroscience’s Dr. Amit Etkin Shares Insights on the Future of Psychiatric Medicines

In an interview with PharmaShots, Dr. Amit Etkin, CEO and Founder of Alto Neuroscience shared his views on its clinical stage pipeline in the emerging hot precision psychiatry space. He also put his views on the funding received by the company for the development of its pipeline. Shots: Using precision psychiatry, the company’s human data R&D platform identifies brain biomarkers…
January 3, 2022

Read more

Load more